Dr. Paul K. Pickrell, MD
Rheumatology (Rheumatology Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 1996, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
TX license K0997 (first issued 1996; active) · UT license 11711039-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Austin, TX | 87 |
| Hydroxychloroquine Sulfate Other prescribers in Austin, TX | 69 |
| Methotrexate (methotrexate sodium) Other prescribers in Austin, TX | 64 |
| Prednisone Other prescribers in Austin, TX | 60 |
| Oxycodone Hcl Other prescribers in Austin, TX | 58 |
| Zolpidem Tartrate Other prescribers in Austin, TX | 48 |
| Gabapentin Other prescribers in Austin, TX | 42 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Austin, TX | 30 |
| Tizanidine Hcl Other prescribers in Austin, TX | 24 |
| Constulose (lactulose) Other prescribers in Austin, TX | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 55 payments worth $904 in total to this clinician.
| AbbVie Inc. | $629 |
|---|---|
| UCB, Inc. | $93.91 |
| E.r. Squibb & Sons, L.l.c. | $56.60 |
| Pfizer Inc. | $53.34 |
| Amgen Inc. | $38.04 |
| AstraZeneca Pharmaceuticals LP | $32.80 |
| Food and Beverage | $904 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 35 industry-funded studies in 2025, from 12 companies. The companies reported $1,866,362 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA
AstraZeneca Pharmaceuticals LP - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc. · Completed · NCT05831111 - Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
AbbVie Inc. · Recruiting · NCT06865105 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc. · Active, not recruiting · NCT05164094 - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.